Edgar Filing: Hamel Lawrence G - Form 4

Form 4	ence G										
March 05, 20									OMB A	PPROVAL	
FORM	UNITED S	TATES		ITIES Al hington, 1			NGE (COMMISSION		3235-0287	
Check this if no long subject to Section 16 Form 4 or			GES IN F SECURI	Expires:January 31Expires:2005Estimated averageburden hours perresponse0.5							
obligation may conti	Form 5 obligations may continue.Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,See InstructionSection 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940										
(Print or Type R	esponses)										
			2. Issuer Name and Ticker or Trading Symbol ACELRX PHARMACEUTICALS				-	5. Relationship of Reporting Person(s) to Issuer			
			INC [AC		VIACEU	IIC <i>F</i>	123	(Cheo	ck all applicable	;)	
(Last) C/O ACELR PHARMACI GALVESTO	X EUTICALS, INC	iddle) ., 351	3. Date of (Month/Da 03/02/20	-	Insaction			Director X Officer (give below) Chief D			
				mendment, Date Original Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
REDWOOD	CITY, CA 94063	3							More than One Re		
(City)	(State) (Z	Zip)	Table	e I - Non-Do	erivative S	Securi	ties Acc	uired, Disposed o	f, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Executio any		3. Transactio Code (Instr. 8)	on(A) or Di (D) (Instr. 3,	4 and (A) or	d of	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		
Common Stock	03/02/2013			Code V F	Amount 1,549 (1)	(D) D	Price \$ 4.96	26,578	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date		4.	5.	6. Date Exerc			le and	8. Price of	9
Derivative	Conversion	(Month/Day/Year)	Execution Date, if		orNumber	Expiration D		Amou		Derivative	Ι
Security	or Exercise		any	Code	of	(Month/Day/	Year)		rlying	Security	S
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Derivative	e		Secur	ities	(Instr. 5)	E
	Derivative				Securities			(Instr	. 3 and 4)		(
	Security				Acquired						F
					(A) or						F
					Disposed]
					of (D)						(
					(Instr. 3,						
					4, and 5)						
									Amount		
						_			or		
						Date	Expiration	Title	Number		
						Exercisable	Date		of		
				Code V	(A) (D)				Shares		
Repo	rting O	wners									
D	Penarting Ow	ner Name / Address			Rel	lationships					
r	ceporting Ow	ner Hame / Audress									

Edgar Filing: Hamel Lawrence G - Form 4

Reporting Owner Manie / Address	Director	10% Owner	Officer	Other
Hamel Lawrence G C/O ACELRX PHARMACEUTICALS, INC. 351 GALVESTON DRIVE REDWOOD CITY, CA 94063			Chief Development Officer	
Signatures				

Signatures

/s/ James Welch,	03/05/2013
attorney-in-fact	05/05/2015

**Signature of Reporting Person

Explanation of Responses:

If the form is filed by more than one reporting person, see Instruction 4(b)(v). *

Date

- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The shares were withheld to satisfy tax liability upon vesting 25% of the restricted stock units of the Company, previously reported on (1) March 4, 2011.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

9. Nt

Deriv

Secu

Bene Own Follo Repo Trans (Inst